What is Hologic?
Women's health diagnostics and medical devices company with ~$4.1B of FY2025 revenue and enterprise healthcare scale.
- Category
- Women's health diagnostics and medical devices
- Headquarters
- Marlborough, MA
- Founded
- 1985
- Employees
- 7,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: HOLX; ~$14B market cap
What is Hologic?
Hologic is a public women's health diagnostics and medical devices company headquartered in Marlborough, MA. It reported ~$4.1B of FY2025 revenue and operates at global enterprise scale.
Hologic operates in women's health diagnostics and medical devices with a portfolio spanning Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company reported ~$4.1B of FY2025 revenue, employs about 7,000+, and trades as Nasdaq: HOLX. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Hologic is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, Hologic is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does Hologic offer?
Hologic offers healthcare products and services across Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Molecular diagnostics· Diagnostics
- Breast imaging· Breast health
- GYN surgical· Surgical
- Skeletal health· Imaging
- Panther platform· Diagnostics
- Mammography systems· Imaging
- Aptima assays· Diagnostics
How does Hologic make money?
Hologic sells diagnostic instruments and assays, breast-imaging systems, surgical products, service, and related consumables with a focus on women's health.
Hologic sells diagnostic instruments and assays, breast-imaging systems, surgical products, service, and related consumables with a focus on women's health. In FY2025, that model produced ~$4.1B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is instrument-, reagent-, assay-menu-, imaging-system-, service-, and contract-volume based; recurring diagnostics consumables and installed-base service are important to margin quality. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads Hologic?
Hologic is led by Stephen P. MacMillan, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Stephen P. MacMillanChairman, President and Chief Executive OfficerCEO since 2013Leads Hologic's women's-health strategy and M&A program.
- Karleen ObertonChief Financial OfficerCFO since 2018Finance leader for diagnostics, imaging, and capital allocation.
- Esmeralda NegronPresident, Diagnostics SolutionsSenior executive leadershipLeads molecular diagnostics and Panther platform priorities.
- Erik AndersonPresident, Breast and Skeletal Health SolutionsSenior executive leadershipLeads breast imaging and skeletal health businesses.
How do you contact Hologic's leadership?
Hologic publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investors@hologic.com) or official contact forms rather than guessed personal addresses.
investors@hologic.com is a public investor/contact route; personal executive email format not verifiedHow much funding has Hologic raised?
Hologic is a mature public company, not a venture-backed startup. It trades as Nasdaq: HOLX, had an approximate ~$14B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
Hologic's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1985, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported ~$4.1B of FY2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: Hologic has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did Hologic get here?
Hologic grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1985Company foundedHologic begins as a medical imaging company.
- 1990IPOHologic lists publicly.
- 2017Cynosure divestiture processPortfolio focus shifts back toward diagnostics and women's health.
- 2020COVID testing surgePanther molecular diagnostics platform scales materially.
- 2025Endomagnetics and Gynesonics integrationsHologic expands breast surgery and gynecologic therapy capabilities.
- 2025FY25 revenue growthHologic reports fourth-quarter FY2025 revenue above $1B.
Who are Hologic's competitors?
Hologic competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- Roche DiagnosticsMolecular diagnostics and women's health assay competitor.
- Siemens HealthineersImaging and diagnostics competitor.
- GE HealthCareBreast imaging and diagnostic imaging competitor.
- Becton DickinsonDiagnostics and women's health specimen/workflow competitor.
- QiagenMolecular diagnostics and sample-prep competitor.
Hologic — frequently asked questions
